ACOX1 and Hepatic fibrosis: Combining ACOX1-specific inhibitors, such as 10,12-tricosadiynoic acid, with middle or low doses of OCA has been shown to effectively improve liver function, steatohepatitis and liver fibrosis in animal models, with comparable efficacy to high doses of OCA, but without the adverse effects on LDL and HDL levels.